Abstracts tagged "etanercept and rheumatoid arthritis (RA)"

Abstract Number: 541 • 2019 ACR/ARP Annual Meeting
Multicenter, Evaluator-blinded, Randomized, Non-inferiority Study, to Assess the Efficacy, Safety and Immunogenicity of Etanercept Biosimilar (EtaBS) vs. Reference Etanercept (EtaRef) in Combination with Methotrexate for the Treatment of Patients with Rheumatoid Arthritis
Ingrid Strusberg¹, Daniel Siri ², Maria Correa ³, Santiago Scarafia ⁴, Rodolfo Pardo Hidalgo ⁵, Alberto Spindler ⁶, Patricio Tate ⁷, Horacio Venarotti ⁸, Jorge Velasco Zamora ⁹, Gustavo Citera ¹⁰, Eduardo Mysler ¹¹, Ezequiel Klimovsky ¹², Andrea Federico ¹², Gabriela Eizikovits ¹², Lucas Cordeiro ¹³ and Nestor Lago ¹³, ¹Instituto Strusberg, Córdoba, Argentina, ²Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ³Consultorios Reumatológicos Pampa, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Municipal "San Cayetano", Buenos Aires, Buenos Aires, Argentina, ⁵CER San Juan, San Juan, Argentina, ⁶Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁷OMI Centro Médico, Buenos Aires, Argentina, ⁸Atención Integral en Reumatología – AIR, Buenos Aires, Argentina, ⁹Instituto Médico CER, Quilmes, Argentina, ¹⁰Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ¹¹Organización Médica de Investigación, Buenos Aires, Argentina, ¹²QUID Quality In Drugs SRL, BUENOS AIRES, Argentina, ¹³Gema Biotech SAU, Buenos Aires, Argentina
Background/Purpose: Enerceptan® (EtaBS) has been developed as a proposed biosimilar of etanercept. Phase I study demonstrated pharmacokinetic equivalence with EtaRef.Methods: A multicenter, non-inferiority, randomized, assessor -blinded,…
Abstract Number: 592 • 2018 ACR/ARHP Annual Meeting
Improved Response to Etanercept Is Associated with Serum Vitamin D Levels in Rheumatoid Arthritis
W Dankers¹, Pascal HP de Jong², S Heil³, S van den Berg³, A Weel⁴, JMW Hazes⁵, E Colin⁶ and Erik Lubberts⁷, ¹Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Clinincal Chemistry, Erasmus MC, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁵Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁶ZGT Almelo, Deventer, Netherlands, ⁷Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands
Background/Purpose: Although treatment of rheumatoid arthritis (RA) has significantly improved during the past decades, many patients do not adequately respond or become resistant to current…
Abstract Number: 2994 • 2018 ACR/ARHP Annual Meeting
Costs Associated with Non-Medical Switching from Originator to Biosimilar Etanercept in Patients with Rheumatoid Arthritis in the UK
Kateryna Onishchenko¹, Stamatia Theodora Alexopoulos¹, Cinzia Curiale² and Miriam Tarallo², ¹Consulting at McCann Health, London, United Kingdom, ²Pfizer, Rome, Italy
Background/Purpose: To estimate the cost impact of non-medical switching from originator etanercept (ETN) to biosimilar ETN in patients with rheumatoid arthritis (RA) in the UK.…
Abstract Number: 2797 • 2017 ACR/ARHP Annual Meeting
Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study
Arthur Kavanaugh¹, Yannick Allanore², Eugeniusz J. Kucharz³ and Goran Babic⁴, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Department of Rheumatology, Cochin Hospital, Paris Descartes University, Paris, France, ³Department of Internal Medicine and Rheumatology, Medical University of Silesia, Katowice, Poland, ⁴Clinical development, Biopharmaceuticals, Hexal AG, a Sandoz company, Holzkirchen, Germany
Background/Purpose: The biosimilarity of GP2015 and etanercept originator product (ETN) has been previously demonstrated in patients with chronic plaque-type psoriasis.1 The randomized, double-blind, phase 3…
Abstract Number: 2441 • 2017 ACR/ARHP Annual Meeting
A Phase III, Multicenter, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Similarities between LBEC0101 and Etanercept Reference Product in Terms of Efficacy and Safety in Patients with Active Rheumatoid Arthritis Inadequately Responding to Methotrexate
Hiroaki Matsuno^1,2, Masato Tomomitsu³, Atsushi Hagino³, Seonghye Shin⁴, Jiyoon Lee⁴ and Yeong Wook Song^5,6, ¹Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ²Institute of Medical Science, Tokyo Medical University, Tokyo, Japan, ³Mochida Pharmaceutical Co.,Ltd., Tokyo, Japan, ⁴Clinical Development, LG Chem, Ltd., Seoul, Korea, Republic of (South), ⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), ⁶Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Medical Research Center, Seoul National University, Seoul, Korea, Republic of (South)
Background/Purpose: LBEC0101 has been developed as a biosimilar to the etanercept reference product (ETN-RP). This study was to evaluate the similarities between LBEC0101 and ETN-RP…
Abstract Number: 2447 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Tolerability of Benepali in Rheumatoid Arthritis Patients Switched from Enbrel
Sarah Dyball¹, Victoria Hoskins², Sharon Christy-Kilner² and Sahena Haque³, ¹Rheumatology, University Hospitals of South Manchester NHS Foundation Trust, Manchester, United Kingdom, ²University Hospitals of South Manchester NHS Foundation Trust, Manchester, United Kingdom, ³Rheumatology department, University Hospitals of South Manchester NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: Benepali, the etanercept biosimilar, is licenced in the UK for rheumatoid arthritis (RA) and costs less than Enbrel. This study aimed to evaluate the…
Abstract Number: 591 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
Louis Bessette¹, Majed Khraishi², Alan J Kivitz³, Arunan Kaliyaperumal⁴, Rama Grantab⁵, Melanie Poulin-Costello⁵, Maya Isaila⁵ and David Collier⁴, ¹Rhumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ²Medical Consultants of West Newfoundland, Western Memorial Hospital, Corner Brook, NF, Canada, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Amgen Canada Inc., Mississauga, ON, Canada
Background/Purpose: When a tumor necrosis factor inhibitor (TNFi) fails in a patient with moderate to severe rheumatoid arthritis (RA), new American College of Rheumatology (ACR)…
Abstract Number: 2526 • 2016 ACR/ARHP Annual Meeting
TNF Blocker Concentrations or Detection of Antibodies Against Anti-TNF before a Tapering Process Are Not Predictive to Relapse
Hubert Marotte^1,2, Mélanie Rinaudo-Gaujous³, Stéphane Paul^3,4 and Bruno Fautrel⁵, ¹SAINBIOSE INSERM U1059 and Rheumatology department, University of Lyon and University Hospital of Saint Etienne, Saint Etienne, France, ²Rheumatology Department, University Hospital of Saint-Etienne, Saint-Etienne, France, ³Laboratory of Immunology and immunomonitoring, CIC CIE3 Inserm Vaccinology, GIMAP EA3064, Hôpital Nord, Saint-Etienne, France, ⁴Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France, ⁵Rheumatology, Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: The goal of rheumatoid arthritis (RA) strategy is to reach remission or at least a low disease activity. When this goal is reached, no…
Abstract Number: 2579 • 2016 ACR/ARHP Annual Meeting
Etanercept Treatment Does Not Adversely Affect Traditional Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis
Atul A. Deodhar¹, Bojena Bitman², Yue Yang² and David Collier³, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²Amgen Inc., South San Francisco, CA, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular (CV) disease. This analysis evaluated changes in metabolic and lipid CV risk factors…
Abstract Number: 477 • 2015 ACR/ARHP Annual Meeting
On-Demand Use of Etanercept Only for Disease Flares Reduced the Disease Activity Score and Structural Damage Equivalent to Fully-Use of Etanercept in RA Patients
Kentaro Inui¹, Tatsuya Koike², Masahiro Tada³, Yuko Sugioka², Kenji Mamoto⁴, Tadashi Okano⁴, Akira Sakawa⁵, Kenzo Fukushima⁶ and Hiroaki Nakamura⁴, ¹Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic Surgery, Osaka City General Hospital, OSAKA, Japan, ⁴Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁵Orthopaedic Surgery, Osaka City Juso Hospital, Osaka, Japan, ⁶Orthopaedic Surgery, Fujiidera Municipal Hospital, Fujiidera, Japan
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) are essential in the treatment of rheumatoid arthritis (RA). Biological DMARDs are particularly recommended for patients with active RA…
Abstract Number: 540 • 2015 ACR/ARHP Annual Meeting
Clinical Relevance of Etanercept Levels and Anti-Etanercept Antibodies in Long-Term Treatment of Rheumatoid Arthritis Patients
Susanne Drynda and Jörn Kekow, Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany
Background/Purpose: Biological compounds have belonged to the therapeutic options for the treatment of rheumatoid arthritis for about 15 years. The application of biological substances is…
Abstract Number: 598 • 2015 ACR/ARHP Annual Meeting
Economic Impact of Decreasing Adalimumab and Etanercept Doses and Drug Monitoring in Patients with Rheumatoid Arthritis in Clinical Remission: Preliminary Study from a Local Biologics Unit
José Rosas¹, Francisca Llinares-Tello², José Miguel Senabre¹, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Xabier Barber³, Ana Pons⁴, Catalina Cano⁴, Marisa Lorente⁵ and Juan Molina⁶, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ²Clinical Analysis, Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain, ³Centro de Investigación Operativa, Miguel Hernández University, Elche, Spain, ⁴Hospital Marina Baixa, Nursing, Villajoyosa, Spain, ⁵Marina Baixa Hospital, Nursing, Villajoyosa, Spain, ⁶Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain
Background/Purpose: To evaluate the economic impact of adalimumab (ADL) and etanercept (ETN) dose reduction (by decreasing treatment frequency) and drug monitoring in patients with rheumatoid…
Abstract Number: 2739 • 2015 ACR/ARHP Annual Meeting
Survival of Etanercept (ETN) Responders after Methotrexate (MTX) Failure When ETN Is Initiated As Mono or Combination Therapy or after MTX Withdrawal from ETN/MTX Combination in Long Standing Rheumatoid Arthritis (RA). a Single Center Retrospective Study
Edward C. Keystone¹, Abdulaziz ALKhalaf^2,3, Sabri ALSaeedi^4,5, Mosaab Makkawy^4,6, Deborah Weber⁷ and Daming Lin⁸, ¹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Rheumatology Division, Medicine Department, UNIVERSITY OF TORONTO/Mount Sinai Hospital, Toronto, ON, Canada, ³Rheumatology Division, Medicine Department, King Saud University, Riyadh, Saudi Arabia, ⁴Rheumatology Division, Medicine Department, UNIVERSITY OF TORONTO/ Mount Sinai Hospital, Toronto, ON, Canada, ⁵Rheumatology Division, Medicine Department, King Fahd Hospital, Jeddah, Saudi Arabia, ⁶Rheumatology Division, Medicine Department, Prince Mohammad Bin Abdulaziz Hospital, Riyadh, Saudi Arabia, ⁷Advanced Therapeutics, Mt Sinai Hosp 2nd Floor 02-205, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: The long term sustainability of ETN as monotherapy (mono) or in combination (combo) with methotrexate (MTX) is uncertain in patients with longstanding RA responding…
Abstract Number: 2924 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis
Meghna Jani¹, Hector Chinoy^1,2, Richard B. Warren³, Christopher E.M Griffiths³, Ann W. Morgan⁴, Anthony G. Wilson⁵, Kimme L. Hyrich¹, John Isaacs⁶, Darren Plant^1,2 and Anne Barton^1,7, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³Dermatology Centre, University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland, ⁶Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose Up to 40% of RA patients on anti-TNF treatment fail to respond either due to primary inefficacy or loss of response. One explanation is…
Abstract Number: 2418 • 2014 ACR/ARHP Annual Meeting
Treatment Pattern and Direct Cost of Biologics for Rheumatoid Arthritis Patients: A Real-World Analysis of Nationwide Japanese Claims Data
Naonobu Sugiyama M.D., Ph.D¹, Tatsunori Murata, M.S.², Yosuke Morishima³, Yuri Fukuma⁴, Yoshiyuki Shibasaki⁴ and Lisa Marshall⁵, ¹Medical Affairs, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ²Health Economics Research Group, CRECON Research and Consulting Inc., Tokyo, Japan, ³RA & Inflammation Area Medical Affairs Department, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ⁴Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ⁵Inflammation Immunology Disease Group, Pfizer Inc. Inflammation Immunology Disease Group, Collegeville, PA
Background/Purpose Biologics such as etanercept (ETN), adalimumab (ADA), infliximab (IFX) and tocilizumab (TCZ) have led dramatic improvement in the treatment of rheumatoid arthritis (RA), but…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].